Activity ID
11041Expires
April 21, 2025Format Type
EnduringCME Credit
0.25Fee
$30CME Provider: American Medical Association
Description of CME Course
The same medications and treatments are not universally effective for every patient. As consumer knowledge of genetics increases, more patients will be coming to you with a direct-to-consumer (DTC) genetics test in hand. What expectations will your patients have? How does Pharmacogenomics (PGx) data help us determine which medication will work better for a specific patient? This course will answer those questions by framing PGx from the perspective of the patient.
Disclaimers
1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Allergy and Immunology
Anesthesiology
Colon and Rectal Surgery
Family Medicine
Medical Genetics and Genomics
Nuclear Medicine
Ophthalmology
Orthopaedic Surgery
Pathology
Physical Medicine and Rehabilitation
Plastic Surgery
Preventive Medicine
Psychiatry and Neurology
Radiology
Thoracic Surgery
Urology
Commercial Support?
NoNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
1. Recognize drivers for implementation of pharmacogenomics from the patient's perspective
2. Identify common patient communication challenges regarding PGx
3. Explain common pharmacogenomic equity opportunities and challenges
Keywords
Adverse Drug Events, Pharmacogenetics, Clinical Pharmacy and Pharmacology
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
DOI
10.1001/ama.2021.0001575
